×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 ... [206]
复旦大学上海医学... [109]
山东大学 [78]
合肥物质科学研究院 [29]
四川大学 [25]
上海中医药大学 [22]
更多...
内容类型
期刊论文 [554]
会议论文 [80]
学位论文 [1]
发表日期
2023 [1]
2022 [9]
2021 [13]
2020 [10]
2019 [72]
2018 [98]
更多...
学科主题
Oncology [2]
oncology [2]
Biochemist... [1]
Demography [1]
Oncology; ... [1]
Pharmacolo... [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共635条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I
期刊论文
BMC MEDICINE, 2023, 卷号: 21, 期号: 1
作者:
Yuankai Shi
;
Jianying Zhou
;
Yanqiu Zhao
;
Bo Zhu
;
Liangming Zhang
收藏
  |  
浏览/下载:0/0
  |  
提交时间:2024/05/07
The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
期刊论文
CANCER MEDICINE, 2022
作者:
Yu, Xiaoqing
;
Si, Jinfei
;
Wei, Jingwen
;
Wang, Yanling
;
Sun, Yan
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2022/12/23
EGFR-TKIs
non-small cell lung cancer (NSCLC)
real-world study
survival outcome
The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
期刊论文
CANCERS, 2022, 卷号: 14
作者:
Xie, Mingying
;
Li, Na
;
Xu, Xiaoling
;
Xu, Yanjun
;
Li, Hui
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2022/12/22
liver metastasis
non-small cell lung cancer
PD-L1
PD-1
PD-L1 inhibitor
CD8+T cell
Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report
期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:
Fu, Meng
;
Feng, Chun-Mei
;
Xia, Da-Qing
;
Ji, Zi-Mei
;
Xia, Huai-Ling
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2022/12/23
savolitinib
MET exon 14 skipping
neoadjuvant therapy
non-small cell lung cancer
targeted therapy
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non-small cell lung cancer (NSCLC).
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:
Zhou, Caicun
;
Ren, Shengxiang
;
Luo, Yongzhong
;
Wang, Lei
;
Xiong, Anwen
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2022/12/23
Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
期刊论文
BMC PULMONARY MEDICINE, 2022, 卷号: 22
作者:
Wang, Wenxian
;
Shao, Lan
;
Xu, Yibing
;
Song, Zhengbo
;
Lou, Guangyuan
收藏
  |  
浏览/下载:18/0
  |  
提交时间:2022/12/23
Non-small cell lung cancer
Prognosis
Angiogenesis
Tyrosine kinase inhibitors
Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
期刊论文
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 卷号: 11
作者:
Gu, Xiaodong
;
Wang, Wenxian
;
Wu, Wei
;
Zhang, Yiping
;
Shao, Lan
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2022/12/22
Non-small cell lung cancer (NSCLC)
HIVEP1-ALK
alectinib
intergenic region (IGR)
case report
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk
期刊论文
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 页码: 23
作者:
He, Bing-Xi
;
Zhong, Yi-Fan
;
Zhu, Yong-Bei
;
Deng, Jia-Jun
;
Fang, Meng-Jie
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2022/06/10
Tumor biomarkers
immunotherapy
lung neoplasms
programmed cell death 1 receptor (PD-1 receptor)
biostatistics
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
期刊论文
NPJ PRECISION ONCOLOGY, 2022, 卷号: 6
作者:
Zhang, Yongchang
;
Huang, Zhe
;
Zeng, Liang
;
Zhang, Xiangyu
;
Li, Yizhi
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2022/05/05
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
期刊论文
LANCET ONCOLOGY, 2022, 卷号: 23
作者:
Zhou, Qing
;
Chen, Ming
;
Jiang, Ou
;
Pan, Yi
;
Hu, Desheng
收藏
  |  
浏览/下载:104/0
  |  
提交时间:2022/03/21
©版权所有 ©2017 CSpace - Powered by
CSpace